Venarus 100 mg + 900 mg

Venarus® is indicated for the therapy of symptoms of chronic venous diseases (elimination and relief of symptoms). Therapy for symptoms of venous-lymphatic insufficiency:

• cramps in the lower limbs;

• sensation of heaviness and fullness in the legs;

• pain;

• leg fatigue. Therapy for manifestations of venous-lymphatic insufficiency:

• swelling of the lower limbs;

• trophic changes in the skin and subcutaneous tissue;

• venous trophic ulcers. Symptomatic therapy of acute and chronic hemorrhoids.

Method of administration and doses

Orally, preferably in the morning, during meals.
The recommended dose for venous-lymphatic insufficiency is 1 tablet/day.
The risk on the tablet is intended solely for division to facilitate swallowing.
The duration of the treatment course may last several months (up to 12 months). In case of recurrence of symptoms, upon the doctor's recommendation, the treatment course may be repeated.
The recommended dose for acute hemorrhoids is 3 tablets/day (1 tablet in the morning, afternoon, and evening) for 4 days, then 2 tablets/day (1 tablet in the morning and evening) for the next 3 days.
The recommended dose for chronic hemorrhoids is 1 tablet/day.

Composition

1 film-coated tablet contains:
active ingredients:
diosmin (calculated as 100% substance) 900 mg,
hesperidin (calculated as 100% substance) 100 mg.
excipients: microcrystalline cellulose, sodium carboxymethyl starch (sodium starch glycolate), gelatin, talc, magnesium stearate;
excipients of the tablet coating: hypromellose (hydroxypropylmethylcellulose), macrogol 6000
(polyethylene glycol 6000), sodium lauryl sulfate, magnesium stearate, titanium dioxide, iron oxide red dye, iron oxide yellow dye.

Description of the dosage form

Film-coated tablets of orange-pink color, biconvex, elongated shape, with rounded ends, with a score line.
In a cross-section - a core from grayish-yellow to brownish-gray color.

Contraindications

Increased sensitivity to active components or excipients included in the preparation.
Not recommended during breastfeeding.
Use during pregnancy and breastfeeding
Animal experiments did not reveal teratogenic effects. To date, there have been no reports of any side effects when the drug is used by pregnant women.
Due to the lack of data regarding the excretion of the drug in breast milk, the use of the drug during breastfeeding is not recommended.
Reproductive toxicity studies did not show any effects on reproductive function in rats of both sexes.

Special instructions

Before starting to take the drug Venarus®, it is recommended to consult a doctor. In case of exacerbation of hemorrhoids, the prescription of Venarus® does not replace specific treatment for other anal disorders. The duration of treatment should not exceed the periods specified in the section "Method of application and doses." If symptoms do not disappear after the recommended course of therapy, a consultation with a proctologist should be sought, who will select further therapy.

In the presence of venous circulation disorders, the maximum effect of treatment is achieved by combining therapy with a healthy (balanced) lifestyle: it is advisable to avoid prolonged sun exposure, long periods of standing, and it is also recommended to reduce excess body weight. Walking and, in some cases, wearing special stockings, help improve blood circulation.

Contact a doctor immediately if your condition worsens or if there is no improvement during treatment.

Effect on the ability to drive vehicles and operate machinery. No effect.

Section: Side Effects

The frequency of adverse reactions is presented as follows: very often (≥1/10 cases); often (≥1/100 and

Section: Overdose

There are no reported cases of overdose.
Treatment: seek medical attention immediately.

Interaction

Not noted.
It is important to inform the attending physician about all medications being taken.

Pharmacodynamics

Venarus® has angioprotective and venotonic effects. It reduces the distensibility of veins, increases their tone, and decreases venous stasis; it lowers permeability and fragility of capillaries and increases their resistance; it improves microcirculation and lymphatic drainage.
With systematic use, it reduces the severity of clinical manifestations of chronic venous insufficiency of both organic and functional nature in the lower extremities. The optimal dose-effect ratio is observed with a daily intake of 1000 mg.

Pharmacokinetics

The main excretion of the drug occurs through the intestines. On average, about 14% of the administered amount of the drug is excreted through the kidneys.
T1/2 is 11 hours.
The drug Venarus® undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Description

Venarus is a medication intended for the treatment of venous system diseases. The drug contains two main components: diosmin and hesperidin. These substances improve microcirculation, reduce vascular permeability, and help decrease swelling.

Venarus should be taken only as prescribed by a doctor; the dosage and duration of treatment depend on the severity of the condition. The medication contains 60 film-coated tablets.

Before using Venarus, it is necessary to read the instructions and consult a doctor.